This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can Solid European Sales Boost Inogen (INGN) in Q2 Earnings?
by Zacks Equity Research
Strong performance in Europe is likely to boost Inogen's (INGN) top line in Q2. However, decline rental-revenues is a concern.
Intuitive Surgical's FDA Approval for SureForm to Aid Surgery
by Zacks Equity Research
Intuitive Surgical's (ISRG) SureForm 60 stapler receives FDA approval; strengthens its profile for minimally invasive surgical solutions.
MASI or STE: Which Is a Better Investment Option Right Now?
by Zacks Equity Research
Masimo's (MASI) and STERIS' (STE) strong expected growth rates and impressive price performance make them close contenders in the Medical Instruments space.
Here's Why You Must Add STERIS (STE) to Your Portfolio Now
by Zacks Equity Research
STERIS' (STE) acquisition of U.K.-based outsourced sterilization services provider, Synergy Health plc, remains one of its key strategic moves.
Medical Device Firms in Focus on Expanded R&D Scope: 5 Picks
by Zacks Equity Research
The suspension of the Medical Device Tax, the evolution of mechatronics and big data in the MedTech space make some of the stocks lucrative picks for investment.
Mechatronics for Healthcare: 3 MedTech Stocks to Bet On
by Nabaparna Bhattacharya
Here we analyze how Medical Mechatronics is creating new opportunities in MedTech for investors who are keen on putting their money in the healthcare space for longer-term gains.
Medical Device Industry Outlook - June 2018
by Zacks Equity Research
The medical device industry's global annual sales is forecast to rise more than 5% a year to reach nearly $800 billion by 2030.
Why Is STERIS (STE) Up 5.2% Since Its Last Earnings Report?
by Zacks Equity Research
STERIS (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is STERIS (STE) Up 7.7% Since Its Last Earnings Report?
by Zacks Equity Research
STERIS (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Buy STERIS (STE) Ahead of Earnings?
by Zacks Equity Research
STERIS (STE) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
4 Top Growth Picks as MedTech Battle Rages On
by Zacks Equity Research
Trump's Obamacare replacement saga has made growth picks great opportunities for investors in MedTech sector.
Civitas Solutions (CIVI) Q3 Earnings Beat, Revenues Miss
by Zacks Equity Research
Civitas Solutions (CIVI) gains on strength in Post-Acute Specialty Rehabilitation Services and Adult Day Health services in Q3. However, tweaked full-year 2017 guidance signals dull prospects.
BioScrip (BIOS) Gains on CORE Initiatives, Competition Rife
by Zacks Equity Research
The company achieved annualized supply chain improvement since the acquisition of Home Solutions.
Why Is STERIS (STE) Up 3.5% Since the Last Earnings Report?
by Zacks Equity Research
STERIS (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
STERIS Continues to Trade Below Industry on Dull Outlook
by Zacks Equity Research
On Mar 16, we issued an updated research report on Ohio-based STERIS plc (STE).
STERIS (STE) Up 3.1% Since Earnings Report: Can It Continue?
by Zacks Equity Research
STERIS (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
STERIS (STE) Cuts 2017 View: Will it See Gloomy Days Ahead?
by Zacks Equity Research
On Feb 09, we issued an updated research report on Ohio-based STERIS plc (STE).
Steris (STE) Q3 Dismal: Earnings Miss Estimates, View Cut
by Zacks Equity Research
Steris Plc (STE) reported third-quarter fiscal 2017 adjusted earnings per share (EPS) of 98 cents, in line with the year-ago quarter.
Top Research Reports for December 29, 2016
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), Danaher (DHR) and Colgate-Palmolive (CL).
Steris Poor Q2 Disappoints, Synergy Health Raises Hope
by Zacks Equity Research
On Dec 7, we issued an updated research report on OH-based STERIS plc (STE).
MedTech Tailwinds at a Glance: Which Stocks to Buy?
by Zacks Equity Research
Positive demographic trends and new product innovation have been the vital force behind the continued uptrend of the sector???s performance.
Rush in Medical Device Investments: Should You Buy These Stocks?
by Zacks Equity Research
Coming to the weakest links in the MedTech sector, we advise investors against names that offer little growth/opportunity in the near term.
Should You Buy Evolving Trends in Medical Devices?
by Zacks Equity Research
Given the U.S. government's pushback on tax-dodging, we expected some sloth to creep into the medical device space as far as M&As are concerned. But to our surprise, M&A activity worldwide has remained fairly stable.
3 Stocks For Buckeye Fans
by Brian Bolan
Ohio State takes on Oregon for the college football national championship, but investors should take a look at Ohio based stocks